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Abstract Studies have shown that LPS-preconditioned
tolerant state could protect against brain injury to subsequent
challenges. We hypothesized astrocytes were directly
involved in the readjustment to confer neuroprotective
effects with LPS pretreatment. High-mobility group box
1(HMGB-1) from LPS-preconditioned astrocytes, presum-
ably serving as a positive regulator, might contribute to the
favorable preconditioned effects. Furthermore, a potential
cellular pathway (PI3K/AKT pathway), has been proposed
for the active regulation of LPS-primed reactive astrocytes
to secrete HMGB-1. In the present study, we used a low
concentration of LPS to directly prime the astrocytes in vitro,
and the subsequent astrocytic reactions, including cytokine
secretion, the expression of transcription factors, and the
release of HMGB-1 were examined after the blockade of the
PI3K pathway. The data showed that LPS preconditioning
could reduce some capacity of astrocytes to subsequent
challenge in vitro. PI3K/AKT pathway was partially
involved in the modulation of the release HMGB-1 from
reactive astrocytes. These findings offer direct evidence
supporting the flexible roles of astrocytes in mediating LPS-
primed neuroprotection, and highlight additional targets for
future attempts to modify the protective effects of astrocytes
through LPS preconditioning.
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Introduction
Classically, preconditioning with a relatively low concen-
tration of lipopolysaccharide (LPS) previously (Beeson
1947; Virca et al. 1989) attenuates the responses to LPS
activation in animals and humans, and in cultured
macrophage/monocytes (in vitro). The pre-exposure of low
doses of harmful stimuli (such as LPS) elicit hyporespon-
siveness for protection against subsequent injurious chal-
lenges (Virca et al. 1989). Recent studies have
demonstrated that a tolerant state could also protect against
brain injury to subsequent challenges including focal
ischemia, cortical spreading depression, brief episodes of
seizure, or exposure to MOG33-35 (Simon et al. 1993;
Kobayashi et al. 1995; Towfighi et al. 1999; Buenafe and
Bourdette 2007). Although the mechanisms involved in
LPS preconditioning are incompletely understood, tran-
sient cellular hyporesponsiveness has been associated with
the decreased inflammatory response, and the reprogram-
ming of cellular signal pathways in response to LPS
priming (Vartanian and Stenzel-Poore 2011). Within the
brain, the inflammation due to immune or neural cells,
including antigen presenting cells (APC) and the microglia,
was thought to be readjusted to confer neuroprotective
effects in response to LPS pretreatment (Rosenzweig et al.
2004).
Astrocytes, the most numerous ‘‘brain-resident’’ neural
cell types in the mammalian brain, have diverse
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constitutions and functions, which may presumably play
roles in the neuroprotective context of LPS-primed
hyporesponsiveness. Generally, reactive astrocytes might
contribute to neuronal remodeling and recovery (Silver and
Miller 2004). Reactive astrocytes after stroke or brain
injury might act as APC or subserve the inflammatory
reaction via the release of various mediators, including
nerve growth factor, interleukins, NO, and so on (Horner
and Gage 2000; Chen and Swanson 2003). Similarly, a
nonhistone DNA-binding molecule, called high-mobility
group box-1 (HMGB-1), was also secreted from the reac-
tive astrocytes (Passalacqua et al. 1998; Kim et al. 2006,
2008). HMGB-1, a pivotal protein might serve as a positive
regulator in coordinating some cell processes, such as
inflammation, proliferation, migration, and survival (Wang
et al. 2004; Sun and Chao 2005; Yang et al. 2005; Ulloa
and Messmer 2006). Studies have shown that HMGB-1
promotes proliferation and sprouting in endothelial cells
(Treutiger et al. 2003; Mullins et al. 2004; Schlueter et al.
2005). This protein also facilitates neurite outgrowth, up-
regulates synaptic proteins, and sustains cell survival in
neurons (Huttunen et al. 1999, 2002; Srikrishna et al.
2002). Hence, during brain injury and inflammation,
HMGB-1 might be secreted from reactive astrocytes as a
potential mediator in the regulation of cerebral remodeling
and recovery, involving the preconditioned favorable
effects to subsequent injurious challenge.
To date, the responses of astrocytes to LPS pretreatment,
and the mechanism that regulates the release of HMGB-1
from astrocytes in response to LPS preconditioning in vitro
have not been completely characterized. In the present
study, we initially investigated the mouse astrocytic reac-
tion through LPS preconditioning and evaluated HMGB-1
expression from reactive cortical astrocytes. Additionally,
during induction, given that several potential cellular
pathways could mediate LPS-primed tolerance, we probed
to PI3K/AKT pathway which was reported to regulate
negatively expression of some inflammatory genes previ-
ously in a LPS challenge (Diaz-Guerra et al. 1999; Cantley
2002; Guha and Mackman 2002; Luyendyk et al. 2008), so
as to further understand mechanisms of HMGB1 in
response to low-dose LPS pre-exposure in astrocytes.
These findings showed that the release of HMGB1 from




Using the modified technique described by McCarthy and
de Vellis (McCarthy and de Vellis 1980), primary astrocyte
culture was prepared from the cerebral cortices of neonatal
C576L/BJ mice (less than 1-day-old) (Guangzhou, China).
Briefly, dissociated cortical cells were suspended in Dul-
becco’s modified Eagle’s medium/nutrient mixture F12
culture medium (DMEM/F12, 1:1) (Gibco, USA) supple-
mented with antibiotics (100 U/ml penicillin, 100 g/ml
streptomycin, and 0.25 g/ml of amphotericin B; Gibco,
USA), and 10% (v/v) heat-inactivated fetal bovine serum
(FBS) (Beyotime, China), and were subsequently cultured
in 75 cm2 flasks. The astrocytes were isolated and purified
at 21 days after plating through trypsinization and shaking.
Non-astrocytic cells including microglia and neurons were
detached from the flasks after shaking and then removed
through trypsinization. The purified astrocytes were
reseeded onto uncoated 6-well plates or slide chambers at a
density of 1 9 106 cells/cm2. Thereafter, the following
experiments were initiated after 24 h. In the culture, the
cells were identified as astrocytes through astrocytic mar-
ker glial fibrillary acidic protein (GFAP) staining, with a
flattened, polygonal morphology. All procedures were
performed in compliance with the Experimental Animal
Management Bill of November 14, 1988 (Decree No. 2 of
the National Science and Technology Commission, Peo-
ple’s Republic of China) and according to the National
Institutes of Health Guide for the Care and Use of Labo-
ratory Animals (NIH Publications No. 80-23), revised in
1996.
LPS Treatment
After the purification of astrocytes for 24 h, the cells were
preconditioned with 0.01 lg/ml LPS in DMEM/F12 med-
ium without FBS and incubated at 37 C for 18 h. There-
after, the cells were re-treated with 1 lg/ml LPS for 24 h,
and subsequently the astroglial cells and supernatants were
harvested. In this experiment, non-treated group, single
dose of LPS-treated groups (0.01 and 1 lg/ml) were
included. The preconditioning paradigm described above
using LPS above was modified according to previous tol-
erance literature in which the preconditioning stimulus was
a low dose of LPS (Cross 2002; Leung et al. 2009; Marsh
et al. 2009; Leung et al. 2012). Moreover, to determine the
role of the PI3K/AKT pathway on the expression of
HMGB-1, one group of astrocytes was treated with the
PI3K/AKT inhibitor of LY294002 (20 lM) for 2 h before
low dose of LPS preconditioning as previously described.
Immunofluorescence
After washing with ice-cold PBS (pH 7.4), the cells were
fixed using 4 % paraformaldehyde for 10 min. Subse-
quently, the cells were further washed three times in PBS
containing 0.1 % Triton X-100, followed by an incubation
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with 3 % bovine serum albumin (BSA) in PBS for 30 min.
Thereafter, the cells were incubated with primary anti-
bodies against the astrocytic marker glial fibrillary acidic
protein (GFAP; 1:100; Millipore) or HMGB-1 (1:200;
Abcam) at 4 C overnight. NF-jb activation was detected
using the Nuclear Translocation Assay Kit, and the
translocation of p65 NF-jb from cytoplasm to the nuclear
revealed the activation of NF-jb. The cells were incubated
with a primary antibody against p65 NF-jb (1:100; Cell
Signaling Technology) at 4 C overnight to determine the
intracellular location of the protein. After washing with
PBS, cells were incubated with goat anti-mouse IgG
against GFAP with AlexaFluor488 (1:400; Beyotime) or
goat anti-rabbit IgG against HMGB-1 conjugated with
FITC (1:200; Beyotime) or goat anti-rabbit IgG against
NF-jb conjugated with Cy3 (1:200; Beyotime) for 1 h at
room temperature. Finally, the nuclei was counterstained
with 4,6-diamidino-2-phenylindole (DAPI), and the cov-
erslips were placed. Immunostaining was analyzed using a
fluorescence microscope (Nikon) interfaced with a digital
charge-coupled device camera and an image analysis
system.
Preparation of Nuclear and Cytoplasmic Extracts
After LPS treatment, astroglial cells were harvested and
washed twice with cold PBS, and nuclear and cytoplasmic
extracts were prepared using a protein extraction kit. We
prepared a single cell suspension containing 1 9 106 cells
in 6-well plates and resuspended the cell pellet using
100 ll of protein extraction reagent A, followed by vor-
texing for 5 s at high speed and incubating on ice for
10 min. Subsequently, 5 ll of protein extraction reagent B
was added, followed by vortexing again for 5 s at high
speed and incubation on ice for 1 min. The cytoplasmic
fraction was extracted through centrifugation at
16,0009g for 5 min at 4 C. Thereafter, the pellet was
resuspended in 25 ll of nuclear extraction reagent con-
taining 1 lM phenylmethanesulfonyl fluoride (PMSF),
followed by vortexing for 15 s at high speed, incubating on
ice for 1 min, and vortexing again for 15 s at high speed.
The same steps were repeated for 30 min, and the nuclear
extract was prepared from the supernatant after centrifu-
gation at 16,0009g for 5 min at 4 C.
Western Blot Analysis
Protein extraction solution (Beyotime) was added to the
cultured cells. The protein concentration was determined
using the Bradford assay (Bio-Rad). The cell lysates (20 lg
per lane) were separated by SDS-PAGE and transferred to
nitrocellulose membranes (Novex). The membranes were
blocked in Tris-buffered saline containing 0.1 % Tween 20
and 5 % BSA for 90 min at room temperature, followed by
incubation overnight at 4 C with monoclonal anti-HMGB-
1 (1:1000, Abcam), anti-NF-jb (1:1000, Cell Signaling
Technology), monoclonal anti-p-AKT antibody (1:1000,
Cell Signaling Technology), anti-AKT antibody (1:1000,
Cell Signaling Technology), monoclonal anti-Histone H3
antibody(1:3000, Abcam), or monoclonal b-actin anti-
body(1:1000, Beyotime). After incubation with peroxidase-
conjugated secondary antibodies (Beyotime) and visual-
ization through enhanced chemiluminescence (Cell Sig-
naling Technology), band intensity was determined using
Image J software.
Cytokine Assay
The levels of TNF-a or IL-6 released from mice astrocytes
into the supernatants were determined using commercially
available ELISA kits (Dakewei, China) according to the
manufacturer’s instructions.
Statistical Analysis
The data are expressed as the mean ± SEM. One-way
ANOVA was used for the statistical analysis using SPSS
17.0 software. A P value\ 0.05 was considered statisti-
cally significant.
Results
Astrocyte Culture and Identification
Using a purified astroglial culture system, 97 % of cells
stained for the astrocytic marker GFAP were identified as
astrocytes (Fig. 1).
Influence of the PI3K/AKT Pathway on TNF-a and
IL-6 Expression from Cultured Astrocytes After
LPS-Preconditioning
As shown in Fig. 2a and b, the levels of TNF-aand IL-6 in
the supernatants were enhanced after 0.01 or 1 lg/ml of
LPS challenge(P\ 0.05, P\ 0.01), compared with the
control group. A smaller dose of 0.01 lg/ml of LPS pre-
treatment for 18 h could also increase TNF-a and IL-6
expression (P\ 0.05, P\ 0.01). However, the levels of
TNF-a from LPS-pretreated astrocytes were lower than
from those in response to LPS challenge at a dose of 1 lg/
ml (P\ 0.01). These findings indicated that a lower dose
of LPS pretreatment can decrease some inflammatory
cytokine secretion from cultured astrocytes with subse-
quent LPS exposure. Additionally, in our study, we used
LY294002 to inhibit PI3K pathway, the data showed TNF-
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a and IL-6 secretion after LPS preconditioning were
reduced significantly (P\ 0.05, P\ 0.01). The results
suggested that the inhibition of PI3K/AKT pathway might
exert suppressive effects on the release of inflammatory
cytokines from cultured astrocytes, which might facilitate
the roles of LPS priming.
The Expression of NF-jb After LPS-
Preconditioning and Influence of PI3K/AKT
Pathway on LPS-Primed NF-jb Expression
The nuclear translocation assay kit was used for detection the
activation of NF-jb. The translocation of p65 NF-jb from
cytoplasm to nuclear reveals the activation of NF-jb. In non-
treated group and 0.01 lg/ml of LPS-treated group, NF-jb
localized predominantly in the cytoplasm, and 1 lg/ml of
LPS-induced increase in astroglial expression of NF-jb was
apparent in both the nuclei and cytoplasm. Nonetheless, with
a lower dose of LPS priming, the expression of NF-jb in the
nuclei was decreased (Fig. 3). These results suggested that
LPS preconditioning could restrict LPS-induced NF-jb
nucleocytoplasmic shutting toward the nuclei. We also used
LY294002 for inhibition of PI3K/AKTpathway, the positive
staining of NF-jb in astrocyte decreased in both cytoplasm
and nuclei. Furthermore, we assessed astrocytic expression
of NF-jb in the cytoplasm and the nuclei with LPS challenge
viaWestern blot analysis. As shown in Fig. 4b, the results of
Western blot showed LPS preconditioning tended to reduce
the nuclear expression of NF-jb with subsequent LPS
exposure, though there was no significant difference statis-
tically. As for the expression of NF-jb in the cytoplasm,
LPS-primed astrocytes showed no obvious changes in
comparison with 1 lg/ml of LPS-treated group. Using
LY294002, the inhibition of PI3K/AKT pathway tended to
restrict theNF-jb expression in both cytoplasm and nuclei of
LPS-primed astrocytes(Fig. 4a and b).
Fig. 1 Astrocytes identification (9200). Immunofluorescence stain-
ing demonstrated the purity of astrocytes in our purified culture
system. The cells in our purified system were stained for the astrocytic
marker glial fibrillary acidic protein (GFAP; green). 97% of cells
were identified as astrocytes; DAPI was used for staining for the
nuclei (blue) (Color figure online)
Fig. 2 Influence of PI3K/AKT pathway on TNF-aand IL-6 levels in
cultured astrocytes after LPS-preconditioning (n = 5). a Influence of
PI3K/AKT pathway on TNF-a levels in cultured astrocytes with LPS
priming(compared with non-treated group, * P\ 0.05; ** P\ 0.01;
compared with the 1 lg/ml of LPS-treated group, ## P\ 0.01;
compared with the LPS-primed group, D P\ 0.05); b. Influence of
PI3K/AKT pathway on IL-6 levels in astrocytes in cultured astrocytes
after LPS priming (compared with the non-treated group,
** P\ 0.01; compared with the LPS-primed group, D P\ 0.05)
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Influence of the PI3K/AKT Pathway on HMGB-1
Expression in Astrocytes with LPS-Preconditioning
Immunofluorescence staining showed that LPS (0.01 and
1 lg/ml) tended to increase the cytoplasmic HMGB-1
expression in astrocytes (Fig. 5). After LPS precondition-
ing, HMGB-1 expression was enhanced with a diffuse
staining in the cytoplasm (Fig. 5). As showed in Fig. 6,
Western blot analysis demonstrated that LPS (0.01 and
1 lg/ml) was inclined to upregulate total HMGB-1
expression in astrocytes. To determine the protein level in
the cytoplasm and nuclei, HMGB-1 in the cytoplasmic and
nuclear extracts was detected. The results showed an
increasing trend in the cytoplasm of LPS-treated (0.01,
1 lg/ml and LPS-primed) astrocytes, which implied a
translocation of HMGB1 into the cytoplasm (Fig. 7a). As
for the nuclear expression of HMGB-1, the results showed
an inclined reduction in LPS-primed group, though no
profound differences in statistics were exhibited (Fig. 7b).
Using LY294002 for inhibition of PI3K pathway, the
inhibitor could effectively suppress AKT phosphorylation
in LPS-primed astrocytes (Fig. 8). Similarly, the expres-
sion of the cytoplasmic and nuclear HMGB-1 from LPS-
primed astrocytes was reduced with the suppression of
PI3K/AKT pathway (Figs. 5, 6, 7). These results suggested
LPS-primed release of HMGB-1 into the cytoplasm was
Fig. 3 The expression of
astrocytic NF-jb after LPS-
preconditioning and influence of
PI3K/AKT pathway on LPS-
primed NF-jb expression. The
astrocytes were preconditioned
using 0.01 lg/ml of LPS for
18 h, followed by treatment
with 1 lg/ml of LPS for 24 h.
Fluorescence microscopy was
used to observe the expression
of astrocytic NF-jb (p65 NF-jb
Ab-targeted NF-jB (red), and
DAPI-targeted nuclei (blue)).
The arrowheads indicated
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attenuated after blocking PI3K/AKT signaling using
LY294002.
Discussion
Low doses of LPS-induced protection against subsequent
re-exposure to LPS in vivo and in macrophages in vitro
(Kanaan et al. 2012; Zhang and Morrison 1993; Hirohashi
and Morrison 1996). Moreover, during some brain injuries
due to cerebral ischemia or autoimmune diseases, LPS
preconditioning is protective as well (Bordet et al. 2000;
Zimmermann et al. 2001; Buenafe and Bourdette 2007; Lin
et al. 2009; Stevens et al. 2011; Vartanian and Stenzel-
Poore 2011; Vartanian et al. 2011; Gesuete et al. 2012).
Recent studies showed that protection conferred by LPS
pretreatment involved the dampening of cellular immune
responsiveness to brain injury, and was associated with
reduced cellular infiltration and activation in the brain
(Rosenzweig et al. 2004; Buenafe and Bourdette 2007;
Vartanian and Stenzel-Poore 2011). Within CNS, the
activation immune cells and/or inflammatory effector
molecules from the neural cells, appeared to participate in
the active modulation of the protective mechanism to LPS
pre-exposure (Zhang and Morrison 1993; Shnyra et al.
1998; Vartanian and Stenzel-Poore 2011).
Reactive astrocytes play complex roles after stroke and
brain injury. Glial scarring is deleterious, as this injury
inhibits dendritic and axonal remodeling in neuronal cir-
cuits (Horner and Gage 2000; Rossi et al. 2007). However,
reactive astrocytes might also secret beneficial mediators
that encourage neuronal and vascular plasticity (Liberto
et al. 2004). In the present study, we hypothesized that
astrocytes might be involved in the cellular reprogramming
of LPS preconditioning, contributing to the protective
effects of these cells. Initially, we examined the responses
of some cytokines and transcript factors in the present
experimental paradigm, which were thought to be closely
related to endotoxin tolerance. The data showed that TNF-
a secretion and the activation of the transcript factor, NF-
jb, in cultured astrocytes were down-regulated during LPS
pretreatment. The suppressive changes of these inflamma-
tory molecules are potent factors involved in the cellular
attenuated responses to LPS re-exposure, which might be
favorable for LPS-primed protective effects. Certainly,
besides TNF-a, other cytokines such as IL-6 were also
influenced by LPS pretreatment. Although previous studies
demonstrated the partial down-regulation of IL-6 with
repeated LPS challenge (Erroi et al., 1993), conversely, our
data showed IL-6 levels from astrocytes were increased in
response to LPS preconditioning. Although the down-reg-
ulation of TNF-a during LPS tolerance being well estab-
lished in the present study, the responses of deferent
mediators are eventually determined through various
kinetic regulatory mechanisms and signal pathways,
thereby governing multiple effects to harmful stimuli. In
addition, whether LPS tolerance partially develops depends
on the challenge model and cell types. Therefore, under-
standably, LPS tolerance did not show global down-regu-
lation of signaling proteins and mediator production in
astrocytes. The LPS-tolerant animals and cells might still
upregulate specific genes and proteins in response to
Fig. 4 The expression of NF-jb in the cytoplasm and nuclei of LPS-
primed astrocytes with LY294002 treatment. The astrocytes were
preconditioned with a lower dose of LPS (0.01 lg/ml) for 18 h,
followed by treatment with 1 lg/ml of LPS for 24 h. The cells were
harvested for preparation of nuclear and cytoplasmic extracts to
assess the nuclear and cytoplasmic NF-jb protein. Western blot
analysis showed LPS preconditioning tended to reduce the nuclear
expression of NF-jb with subsequent LPS exposure. In the cyto-
plasm, LPS-primed astrocytes showed no obvious changes in
comparison with 1 lg/ml of LPS-treated group. Using LY294002 to
inhibit PI3K/AKT pathway, NF-jb expression exhibited a reduction
trend in both cytoplasm and nuclear. The images are representative of
three independent experiments
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further LPS challenge (Vartanian and Stenzel-Poore 2011).
In our study, we also dissected the responses of HMGB-1
from cultured astrocytes to LPS preconditioning. Based on
the results, LPS preconditioning was inclined to enhance
HMGB-1 expression in the cytoplasm, which suggested
LPS priming involved in a release of HMGB-1 into the
cytoplasm. Generally, HMGB-1 is regarded as an
endogenous ‘‘alarmins,’’ which serves as danger signals
and cytokines to promote the activation of the innate
immunity in response to trauma, ischemia/reperfusion, or
infection (Bianchi 2007). In stroke and brain injury,
HMGB-1 might be released from ischemic neurons (Qiu
et al. 2003), brain microglia (Kim et al. 2006), and
activated monocytes/macrophages (Wang et al. 1999;
Andersson et al. 2000), potentially mediating deleterious
inflammatory responses (Andersson et al. 2000; Hayakawa
et al. 2008, 2009). Recent studies have shown that reactive
astrocytes release HMGB-1, which promotes neurovascular
recovery after cerebral ischemia in mice (Hayakawa et al.,
2009). Delayed HMGB-1 signaling in reactive astrocytes
might promote neurovascular remodeling and neurite out-
growth (Huttunen et al. 2000; Treutiger et al. 2003). Thus,
in this regard, HMGB-1 might play biphasic roles in the
diverse pathophysiological processes. During the LPS-
primed tolerance, most of studies have suggested the
benefits of inducing tolerance in the context of
Fig. 5 Influence of the PI3K/
AKT pathway on the expression
of HMGB-1 in astrocytes with
LPS preconditioning. LPS-
preconditioning increased the
translocation HMGB-1 into the
cytoplasm. With the treatment
of LY294002, HMGB-1
translocation was inhibited. The
cells were stained for the anti-
HMGB-1 antibody (green), and
for a nuclei stain DAPI (blue).
Images are representative of
three independent experiments
(Color figure online)
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inflammation milieu. The data obtained in the present study
provided clues about HMGB-1 upregulation in this case.
Although the precise function of HMGB-1 in LPS-priming
astrocytes in vitro was not fully interpreted in current
experiments, the results partially suggest that this molecule
is actively involved in the reprogramming process, and
might be a potential favor for LPS-priming protective
effects in the CNS. Thus, to clarify the precise roles, and
the interactions involving HMGB-1 from the astrocytic
medium and neurons in vitro and in vivo are necessary for
further studies (data not shown).
Addtionally, in the present study, we also probed to one
potential mechanism, that is, the PI3K/AKT pathway, which
controls HMGB-1 regulation during LPS tolerance. Previ-
ously, the activation of PI3K/AKT has been implicated to
play a pivotal role in cytokine secretion and shown to neg-
atively regulate the expression of NF-jb and inflammatory
genes (Guha and Mackman 2002; Luyendyk et al. 2008).
The PI3K activation suppressed LPS-induced lipoprotein
lipase expression in J774 macrophages (Tengku-Muham-
mad et al. 1999) and nitric-oxide synthase in C6 glial cells
(Pahan et al. 1999). Human and rat primary astrocytes were
also negatively regulated by PI3K activation (Pahan et al.
2000). Nevertheless, in contrast to studies showing that the
PI3K/AKT pathway negatively regulates the expression of
inflammatory genes in macrophages, a recent study
demonstrated that the PI3K/AKT pathway positively regu-
lated NF-kb-dependent gene expression in HepG2 cells via
phosphorylation and increased the transactivation activity of
p65 (Luyendyk et al. 2008). It is proved that LPS tolerance
has evolved as a complex counter-regulatory adaptive
inflammatory response. Many signal pathways are recruited
into the reprogramming process. Presently, the PI3K/AKT
pathway has been implicated in the mediation of the LPS-
primed reactive astrocytic upregulation and release of
HMGB-1. We observed that using LY294002 to block the
PI3K pathway inhibited LPS-primed HMGB-1 release from
astrocytes, which was similar to the changes of TNF-a, IL-6,
and NF-kb. Previous studies have suggested that the PI3K
pathway remains open in LPS tolerance. Our results revealed
the positive regulation of HMGB-1 expression and pro-in-
flammatory mediators in LPS-pretreated primary astrocytes.
This pathway might represent an important flexible mecha-
nism to regulate the activity of HMGB-1, and potentially
provides a candidate for modifying and augmenting the
protective effects in astrocytes in response to LPS precon-
ditioning after brain inflammation or injuries. Nonetheless,
considering further perplexities of LPS tolerance in vivo,
and the internal milieu is distinct from that in vitro, deter-
mining how HMGB-1 is co-regulated in other cell types or
signal pathways in the cerebral brain requires more pro-
foundly unraveling.
Fig. 6 HMGB-1 expression of the LPS-primed astrocytes after the
inhibition of the PI3K/AKT pathway. LPS (0.01 and 1 lg/ml)
treatment tended to upregulate total HMGB-1 expression in astro-
cytes. LY294002 effectively reduced the expression of HMGB-1 in
astrocytes (compared with LPS-primed group, * P\ 0.05). The
images are representative of three independent experiments
Fig. 7 HMGB-1 expression in the cytoplasm and nuclei of LPS-
primed astrocytes with LY294002 treatment. Western blot analysis
revealed LPS preconditioning tended to enhance cytoplasmic HMGB-
1. Using LY294002 to inhibit PI3K/AKT pathway, HMGB-1
expression of LPS-primed astrocytes showed a reduction trend in
both cytoplasm and nuclei. The images are representative of three
independent experiments
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In conclusion, with LPS preconditioning, cortical
astrocytes evolved an adjusted cellular response in vitro,
and the PI3K/AKT pathway positively regulated LPS-
primed release of HMGB-1 from astrocytes. These findings
provide insights into the mechanisms underlying LPS
priming and the beneficial actions of resident cells in
response to diverse brain insults.
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